Literature DB >> 15963462

Phosphorylation and binding partner analysis of the TSC1-TSC2 complex.

Mark Nellist1, Peter C Burgers, Ans M W van den Ouweland, Dicky J J Halley, Theo M Luider.   

Abstract

Tuberous sclerosis complex (TSC) is an autosomal dominant benign tumour syndrome caused by mutations to either the TSC1 or TSC2 tumour suppressor gene. The TSC1 and TSC2 gene products, TSC1 and TSC2, form a protein complex that integrates inputs from multiple signalling cascades to inactivate the small GTPase rheb, and thereby inhibit mTOR-dependent cell growth. We have used matrix-assisted laser desorption/ionisation time-of-flight and Fourier transform mass spectrometry to identify TSC1 and TSC2 phosphorylation sites and candidate TSC1 and TSC2 interacting proteins. We identified three sites of TSC2 phosphorylation and a novel site of TSC1 phosphorylation, and investigated the roles of these sites in regulating the activity of the TSC1-TSC2 complex. In addition, we identified three TSC1-TSC2 interacting proteins, including DOCK7 a putative rhebGEF.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15963462     DOI: 10.1016/j.bbrc.2005.05.175

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  15 in total

Review 1.  Regulation of mTORC1 by PI3K signaling.

Authors:  Christian C Dibble; Lewis C Cantley
Journal:  Trends Cell Biol       Date:  2015-07-06       Impact factor: 20.808

2.  Dissection of affinity captured LINE-1 macromolecular complexes.

Authors:  Martin S Taylor; Ilya Altukhov; Kelly R Molloy; Paolo Mita; Hua Jiang; Emily M Adney; Aleksandra Wudzinska; Sana Badri; Dmitry Ischenko; George Eng; Kathleen H Burns; David Fenyö; Brian T Chait; Dmitry Alexeev; Michael P Rout; Jef D Boeke; John LaCava
Journal:  Elife       Date:  2018-01-08       Impact factor: 8.140

3.  Loss of postnatal quiescence of neural stem cells through mTOR activation upon genetic removal of cysteine string protein-α.

Authors:  Jose L Nieto-González; Leonardo Gómez-Sánchez; Fabiola Mavillard; Pedro Linares-Clemente; María C Rivero; Marina Valenzuela-Villatoro; José L Muñoz-Bravo; Ricardo Pardal; Rafael Fernández-Chacón
Journal:  Proc Natl Acad Sci U S A       Date:  2019-03-29       Impact factor: 11.205

Review 4.  TSC1/TSC2 signaling in the CNS.

Authors:  Juliette M Han; Mustafa Sahin
Journal:  FEBS Lett       Date:  2011-02-15       Impact factor: 4.124

5.  Prenylation and membrane localization of Cdc42 are essential for activation by DOCK7.

Authors:  Yeyun Zhou; Jared L Johnson; Richard A Cerione; Jon W Erickson
Journal:  Biochemistry       Date:  2013-06-14       Impact factor: 3.162

Review 6.  Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin.

Authors:  Zhao Zhong Chong; Yan Chen Shang; Shaohui Wang; Kenneth Maiese
Journal:  Prog Neurobiol       Date:  2012-08-15       Impact factor: 11.685

7.  Mice with mutations of Dock7 have generalized hypopigmentation and white-spotting but show normal neurological function.

Authors:  Amanda L Blasius; Katharina Brandl; Karine Crozat; Yu Xia; Kevin Khovananth; Philippe Krebs; Nora G Smart; Antonella Zampolli; Zaverio M Ruggeri; Bruce A Beutler
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-06       Impact factor: 11.205

8.  Brain tumor formation in tuberous sclerosis depends on Erk activation.

Authors:  Jaroslaw Jozwiak; Wieslawa Grajkowska; Katarzyna Kotulska; Sergiusz Jozwiak; Wojciech Zalewski; Agnieszka Zajaczkowska; Marcin Roszkowski; Artur Slupianek; Pawel Wlodarski
Journal:  Neuromolecular Med       Date:  2007       Impact factor: 3.843

Review 9.  The DOCK protein family in vascular development and disease.

Authors:  Clare E Benson; Laura Southgate
Journal:  Angiogenesis       Date:  2021-02-06       Impact factor: 10.658

10.  Genetics and molecular biology of tuberous sclerosis complex.

Authors:  Valerio Napolioni; Paolo Curatolo
Journal:  Curr Genomics       Date:  2008-11       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.